score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Investigate Actionability	Clinical evidence			Mutational Burden	High Mutational Burden								Investigate Actionability	Ipilimumab	CTLA-4 inhibition	Immunotherapy	In a study of malignant melanoma using a discovery cohort of 25 patients and a validation cohort of 39 patients, a significantly higher muational burden was seen in patients with a long-term clinical benefit vs. patients with minimal or no benefit to ipilimumab treatment.	Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371(23):2189-99.	https://doi.org/10.1056/NEJMoa1406498													0				 mutations per Mb		MEL-IPI_Pat85		
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.Q581*	0.0348	431.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0.0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744	0	618.0	0.0405	0.9999	ARID1A p.Q581* (Nonsense)		MEL-IPI_Pat85	MEL-IPI_Pat85-Tumor-SM-53U2Y	MEL-IPI_Pat85-Normal-SM-4NFWH
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.S46Y	0.05	480.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0.0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0	0.0	0.0	0.0	TP53 p.S46Y (Missense)		MEL-IPI_Pat85	MEL-IPI_Pat85-Tumor-SM-53U2Y	MEL-IPI_Pat85-Normal-SM-4NFWH
Investigate Actionability		Guideline		Somatic Variant	ABL1	Missense	p.S162F	0.0647	201.0	0.0	0.0									Investigate Actionability	Dasatinib	BCR-ABL inhibition	Targeted therapy	Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.	National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf						0	131.0	0.2672	0.9525	ABL1 p.S162F (Missense)		MEL-IPI_Pat85	MEL-IPI_Pat85-Tumor-SM-53U2Y	MEL-IPI_Pat85-Normal-SM-4NFWH
Investigate Actionability		Preclinical		Somatic Variant	NFE2L2	Missense	p.V579A	0.0802	162.0	0.0	0.0									Investigate Actionability	Radiation therapy	Radiation	Radiation therapy	In a study of survival after radiation in lung squamous cancer cell lines, NFE2L2 conferred radiation resistance.	Abazeed ME, Adams DJ, Hurov KE, et al. Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer Cancer Research. 2013; 73(20):6289-6298.	https://doi.org/10.1158/0008-5472.can-13-1616						0	0.0	0.0	0.0	NFE2L2 p.V579A (Missense)		MEL-IPI_Pat85	MEL-IPI_Pat85-Tumor-SM-53U2Y	MEL-IPI_Pat85-Normal-SM-4NFWH
Biologically Relevant				Somatic Variant	NTRK1	Missense	p.D270N	0.0559	143.0	4.9e-05	0.0																					0	8.0	0.125	0.0014	NTRK1 p.D270N (Missense)		MEL-IPI_Pat85	MEL-IPI_Pat85-Tumor-SM-53U2Y	MEL-IPI_Pat85-Normal-SM-4NFWH
Biologically Relevant				Somatic Variant	NF1	Missense	p.L90Q	0.031	129.0	0.0	0.0																					0	165.0	0.0485	0.7599	NF1 p.L90Q (Missense)		MEL-IPI_Pat85	MEL-IPI_Pat85-Tumor-SM-53U2Y	MEL-IPI_Pat85-Normal-SM-4NFWH
Biologically Relevant				Somatic Variant	NF1	Splice Site		0.0522	115.0	0.0	0.0																					0	9.0	0.1111	0.0022	NF1  (Splice Site)		MEL-IPI_Pat85	MEL-IPI_Pat85-Tumor-SM-53U2Y	MEL-IPI_Pat85-Normal-SM-4NFWH
Biologically Relevant				Somatic Variant	TPX2	Nonsense	p.Q275*	0.0498	201.0	0.0	0.0																					0	79.0	0.1646	0.5896	TPX2 p.Q275* (Nonsense)		MEL-IPI_Pat85	MEL-IPI_Pat85-Tumor-SM-53U2Y	MEL-IPI_Pat85-Normal-SM-4NFWH
Biologically Relevant				Microsatellite Stability	Supporting variants		PRDM2 p.703_704insP (Insertion), MSH3 p.63_64insAAP (Insertion)																									0				Supporting variants: PRDM2 p.703_704insP (Insertion), MSH3 p.63_64insAAP (Insertion)		MEL-IPI_Pat85		
Biologically Relevant				Mutational Signature	COSMIC Signature 7	version 2	0.708																									0				COSMIC Signature (version 2) 7 (71%)		MEL-IPI_Pat85		
